Last reviewed · How we verify
metforminhydrochloride
metforminhydrochloride is a Small molecule drug developed by Tampere University Hospital. It is currently FDA-approved. Also known as: A10BA02, Diformin, Metformin.
At a glance
| Generic name | metforminhydrochloride |
|---|---|
| Also known as | A10BA02, Diformin, Metformin |
| Sponsor | Tampere University Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- metforminhydrochloride CI brief — competitive landscape report
- metforminhydrochloride updates RSS · CI watch RSS
- Tampere University Hospital portfolio CI
Frequently asked questions about metforminhydrochloride
What is metforminhydrochloride?
metforminhydrochloride is a Small molecule drug developed by Tampere University Hospital.
Who makes metforminhydrochloride?
metforminhydrochloride is developed and marketed by Tampere University Hospital (see full Tampere University Hospital pipeline at /company/tampere-university-hospital).
Is metforminhydrochloride also known as anything else?
metforminhydrochloride is also known as A10BA02, Diformin, Metformin.
What development phase is metforminhydrochloride in?
metforminhydrochloride is FDA-approved (marketed).
Related
- Manufacturer: Tampere University Hospital — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: A10BA02, Diformin, Metformin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing